Compare IDEXX Laboratories, Inc. (IDXX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Orion Office REIT Inc — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Orion Office REIT Inc trades at $2.62 (market cap $151.74M). The key difference: IDEXX Laboratories, Inc. is far larger — about 287.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | ONL | |
|---|---|---|
Market Cap | $43.58B | $151.74M |
Sector | Health | Real Estate |
52-Week High | $766.68 | $3.04 |
52-Week Low | $526.44 | $1.93 |
Enterprise Value | $44.48B | $635.39M |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
ONL trades at $2.67, up 1.52% with mixed technical signals showing bullish oscillators but bearish moving averages. The company faces significant fundamental challenges with revenue declining from $208M in 2022 to $147.65M in 2025 and deep net losses widening to -$139.31M. However, strategic reviews with Wells Fargo and JPMorgan and recent refinancing extensions provide some stability amid ongoing portfolio repositioning toward dedicated use assets.
The outlook remains challenging with persistent losses and declining revenue, though the strategic review and deleveraging progress offer potential catalysts. Key risks include execution of asset sales, office market headwinds, and negative cash flow from operations. Analyst sentiment is divided with 50% buy and 50% hold ratings, reflecting uncertainty about the turnaround strategy's success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
